# PRESERVE-001 (NCT04140526)

> Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04140526
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: OncoC4, Inc.
- Conditions: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma
- Interventions: ONC-392; Pembrolizumab; Docetaxel
- Enrollment: 733
- Primary outcome: Dose limiting toxicity (DLT) in monotherapy
- Primary outcome: Maximal tolerable dose (MTD) in monotherapy
- Primary outcome: Recommended Phase II Dose (RP2D)
- Primary outcome: Rate of treatment related adverse events (TRAE) according to CTCAE v5.0

## Indexed commentary on PRESERVE-001 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=preserve-001-nct04140526